This technology uses engineered proteins called degradons to selectively bind and degrade disease-related proteins, offering a targeted approach for treating diseases.
Background
The field of targeted molecular therapeutics focuses on neutralizing pathogenic proteins responsible for severe diseases, including cancer and neurodegenerative disorders. In many conditions, cellular dysfunction is directly linked to the overexpression, mutation, or toxic accumulation of specific proteins. Consequently, there is a profound clinical need for technologies capable of selectively eliminating these harmful proteins from within the cellular environment. Rather than merely inhibiting protein function temporarily, permanently removing the offending proteins offers a more robust therapeutic strategy to restore normal cellular homeostasis.
Despite this need, current therapeutic approaches face significant limitations. Traditional small molecule inhibitors primarily rely on blocking active sites, leaving a vast majority of the human proteome "undruggable" because many proteins lack accessible binding pockets. While recent degradation strategies attempt to overcome this by hijacking the ubiquitin-proteasome system, they typically depend on recruiting specific E3 ubiquitin ligases. This reliance introduces major vulnerabilities, as target cells frequently downregulate or mutate these ligases, rapidly leading to drug resistance. Furthermore, existing chimeric molecules are often structurally complex, suffering from poor cellular permeability and unfavorable pharmacokinetics, restricting their clinical efficacy.
Technology Description
This technology introduces engineered recombinant polypeptides, known as degradons, designed to selectively eliminate specific proteins within the body. The core architecture of these molecules consists of two distinct functional regions: a target-binding domain and a proteasome-binding domain. The target-binding domain is customized to recognize and attach to specific proteins, particularly those driving various diseases. Once attached, the proteasome-binding domain engages the cell's natural waste disposal machinery to initiate the breakdown of the targeted protein. Furthermore, this solution encompasses specialized expression vectors that encode these degradons, facilitating their delivery and therapeutic application.
This solution is highly differentiated because it moves beyond traditional therapeutic approaches that merely inhibit disease-causing proteins, instead actively orchestrating their complete destruction. By physically linking a disease-specific target to the cellular proteasome, these degradons leverage the body's intrinsic protein-clearing mechanisms to permanently remove harmful molecules. This modular, dual-domain design offers unprecedented versatility, as the target-binding region can be adapted to address a wide array of different diseases. Consequently, this targeted degradation strategy provides a potent, long-lasting therapeutic effect compared to conventional inhibitors, offering a highly adaptable platform for next-generation genetic therapies.
Benefits
- Enables highly selective targeting of specific proteins for degradation.
- Facilitates the direct destruction of disease-causing proteins rather than merely inhibiting their function.
- Offers a versatile, modular design by combining customizable target-binding and proteasome-binding domains.
- Provides novel therapeutic avenues for treating a wide range of protein-associated diseases.
- Supports flexible delivery methods, including direct polypeptide administration or gene therapy via expression vectors.
Commercial Applications
- Targeted protein degradation therapeutics
- Neurodegenerative disease treatments
- Gene therapy vector development
- Targeted cancer therapeutics
- Precision medicine drug discovery
Additional Information
These recombinant polypeptides, termed degradons, comprise a target-binding domain and a proteasome-binding domain. They selectively bind and mediate the degradation of specific target proteins, such as those associated with disease, via the proteasome. Associated expression vectors and therapeutic methods utilizing these polypeptides or vectors are also included for disease treatment.
US Patent 15/773,228
About the inventor
Dr. Andreas Matouschek is a Professor and Associate Dean for Research and Facilities at The University of Texas at Austin in the Department of Molecular Biosciences. Dr. Matouschek’s lab studies the mechanisms of protein machines, protein folding, unfolding, and degradation. His lab’s goal is to understand the biochemical mechanisms of the Ubiquitin Proteasome System (UPS) in a physiologically relevant context, in hopes to translate insights into strategies to interfere in the UPS therapeutically.
